Dextran Sulfate Sodium Salt (MW 35000-45000): Precision Tool for Experimental Colitis Models

Executive Summary: Dextran sulfate sodium salt (MW 35000-45000), supplied by APExBIO (SKU B8205), is a sulfated polysaccharide used as a standard chemical inducer of experimental colitis in murine models [APExBIO product]. DSS induces reproducible disruption of colonic epithelial integrity, triggering acute and chronic intestinal inflammation that mirrors human ulcerative colitis [Xie et al., 2026]. The compound functions by inducing apoptosis in intestinal epithelial cells (IECs) and compromising barrier function, enabling robust evaluation of mucosal repair mechanisms and anti-inflammatory therapeutics. DSS is water-soluble (≥55.5 mg/mL at room temperature) and administered at 2.5–5% (w/w) via drinking water or feed in mouse models [BudiPineKits]. Its antiviral properties, notably against HIV-1, expand its utility in virology research, while its polyanionic nature does not significantly affect blood coagulation pathways [DexSP].

Biological Rationale

Ulcerative colitis (UC) is a chronic, relapsing inflammatory disease of the colon, with intestinal mucosal barrier dysfunction recognized as a primary pathogenic event [Xie et al., 2026]. The integrity of the intestinal epithelium is essential for defense against pathogens and maintenance of homeostasis. DSS (MW 35000-45000) is a polyanionic, sulfated polysaccharide derived from polymerized glucose units. When administered to mice, it targets the colonic epithelium, causing selective injury by inducing apoptosis in IECs. This leads to barrier dysfunction, inflammatory cell infiltration, and mucosal ulceration, faithfully reproducing key features of human UC [IGG-LC]. The DSS-induced colitis model allows for controlled investigation of epithelial damage, repair, and the molecular pathways involved in mucosal regeneration, such as the GPR35-KLF5 metabolic gatekeeping circuit [Xie et al., 2026].

Mechanism of Action of Dextran sulfate sodium salt (MW 35000-45000)

DSS acts primarily via its strong negative charge, imparted by sulfate groups, which interact with proteins and membranes of colonic epithelial cells. Key mechanistic actions include:

• Apoptosis Induction: DSS initiates apoptosis in IECs, leading to focal erosion and ulceration of the epithelium [APExBIO].
• Barrier Disruption: Loss of epithelial integrity increases permeability, allowing gut antigens and microbiota to breach the mucosa and trigger inflammation [IGG-LC].
• Innate Immune Activation: Damaged IECs release danger signals, recruiting neutrophils and macrophages to the site of injury.
• Repair Programming: Epithelial repair involves proliferation and migration of surviving IECs, orchestrated by the GPR35-KLF5 axis in response to metabolic cues (tryptophan–kynurenine–kynurenic acid axis) [Xie et al., 2026].
• Antiviral Activity: DSS inhibits viral adsorption and entry, notably against HIV-1, by blocking interactions between viral particles and host cell surfaces [DexSP].

Evidence & Benchmarks

• DSS (MW 35000-45000) at 2.5–5% in drinking water reliably induces acute colitis within 5–7 days in C57BL/6 mice (weight loss, diarrhea, histological mucosal damage) (BudiPineKits).
• Histological scoring demonstrates reproducible epithelial ulceration and inflammatory cell infiltration, paralleling human UC pathology (Xie et al., 2026).
• DSS-induced barrier dysfunction is quantifiable via FITC-dextran permeability assays and tight junction protein loss (IGG-LC).
• Antiviral efficacy: DSS inhibits HIV-1 viral entry at micromolar concentrations without cytotoxicity (DexSP).
• GPR35-KLF5 signaling is upregulated during epithelial repair after DSS-induced injury, supporting its value in metabolic circuit studies (Xie et al., 2026).

Applications, Limits & Misconceptions

DSS (MW 35000-45000) is a gold-standard tool for modeling intestinal inflammation and epithelial repair. Its core applications include:

• Induction of acute and chronic colitis in murine models for preclinical IBD research.
• Assessment of anti-inflammatory drug candidates and mucosal healing agents.
• Dissection of molecular circuits governing IEC apoptosis, proliferation, and migration (such as GPR35-KLF5).
• Investigation of host-pathogen interactions and epithelial barrier function.
• Evaluation of antiviral agents targeting HIV-1 entry mechanisms.

Researchers should consult this article for foundational protocol details, noting that the current review integrates cutting-edge insights into metabolic sensing and epithelial repair, clarifying the translational scope. For practical optimization and troubleshooting, this Q&A resource addresses frequent laboratory challenges, while our discussion extends these findings with the latest molecular mechanisms. Readers interested in antiviral and epithelial repair applications will find additional mechanistic depth in this analysis—the present article updates these perspectives by linking DSS-induced injury to GPR35-KLF5 signaling in mucosal repair.

Common Pitfalls or Misconceptions

• DSS is not a pathogen: DSS induces chemical, not infectious, colitis. It does not model microbial pathogenesis directly.
• Batch variability matters: Different molecular weights or sources may yield variable results; use validated lots and report MW (35000-45000).
• DSS solutions are not stable long-term: Prepare fresh solutions; prolonged storage reduces efficacy and increases endotoxin risk.
• Not all mouse strains respond identically: Susceptibility varies (e.g., C57BL/6 more sensitive than BALB/c), so strain selection impacts reproducibility.
• Not a direct model for all IBD subtypes: DSS best models ulcerative colitis rather than Crohn’s disease or other IBD forms.

Workflow Integration & Parameters

DSS (MW 35000-45000) is supplied as a solid, water-soluble powder. For experimental colitis induction:

• Concentration: 2.5–5% (w/w) in drinking water, ad libitum, for 5–7 days (acute model) or repeated cycles (chronic model).
• Solubility: ≥55.5 mg/mL in water at room temperature; insoluble in ethanol or DMSO.
• Storage: Store solid at room temperature; use prepared solutions promptly and avoid long-term storage.
• Endpoints: Monitor weight loss, stool consistency, rectal bleeding, and histopathology.
• Controls: Include appropriate vehicle-only and unexposed groups.

For anti-inflammatory or repair studies, interventions are typically administered during or after DSS exposure, with endpoints including IEC proliferation/migration, tight junction protein expression, and GPR35 pathway activation.

Conclusion & Outlook

Dextran sulfate sodium salt (MW 35000-45000) from APExBIO remains an indispensable tool for high-fidelity modeling of ulcerative colitis and epithelial barrier disruption in mice. It enables mechanistic dissection of mucosal damage, repair, and immune responses, supporting translational research in IBD, pharmacology, and virology. Ongoing advances—including insights into the GPR35-KLF5 repair circuit—underscore the value of DSS-based models for preclinical drug discovery and fundamental immunology. As new molecular targets and repair pathways are uncovered, DSS will continue to facilitate robust, reproducible experimentation and accelerate the development of rational therapies for inflammatory and infectious diseases.